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healthy individuals or those of individuals recovering from diarrhea or malnutrition. We 23 establish these communities in a murine immunization model, and show that the dysbiotic gut 24 microbiome, commonly present in areas where malnutrition and diarrhea are common, 25 suppresses the immune response against Vibrio cholerae through the action of CD4 + cells. Our 26 findings suggest that the composition of the gut microbiome at time of immunization may be 27 pivotal for providing robust immunity from oral cholera vaccines, and highlight the importance 28 of the gut microbiome on mucosal immunization responses and vaccine development 29 strategies. 30 31 Importance 32
Diarrhea caused by enteric bacterial pathogens is a recurring and important issue for worldwide 33 health. Cholera, the severe watery diarrhea caused by the bacterium Vibrio cholerae, affects 34 millions of people annually. Currently, there is a lack of effective preventative measures for 35 cholera, due to the uneven performance of oral cholera vaccines. Thus, it is essential to better 36
Introduction 43
Vibrio cholerae is the etiologic agent of cholera, a severe diarrheal disease affecting 44 approximately 3 million people annually, resulting in over 100,000 deaths (1). V. cholerae 45 preferentially colonizes the small intestine, where it releases cholera toxin (CT), which causes 46 profuse watery diarrhea and loss of electrolytes. While the advent of oral rehydration therapy 47 has dramatically reduced mortality from cholera, recent major outbreaks in Yemen and Haiti 48 are reminders of the pressing global public health need to improve cholera prevention 49 strategies. Several oral cholera vaccines (OCVs) have been developed, though they have 50 demonstrated high variance in protective efficacy in field trials (2). While OCVs have been 51
shown to have an efficacy of generally 80%-90% in developed countries, large field studies in 52 developing regions range from 14-50% efficacy (3-7). Two main types of OCVs have been 53 developed, whole-cell killed and live-attenuated. The whole-cell killed vaccine, Dukoral, 54 consisted of inactivated strains of O1 Classical and El Tor biotype V. cholerae as well as 55 recombinant cholera toxin subunit B, the non-enzymatic subunit of cholera toxin (7) . Dukoral 56 showed 50% efficacy in all age groups in a Bangladesh field trial (3), while demonstrating 57 significant vibriocidal titers (a clinical correlate of protection) in 89% of volunteers in the US (4). 58
Another whole-cell killed vaccine, Shanchol, is composed of various O1 Classical and El Tor 59 strains as well as one O139 strain (7). In children aged 1-5 years in Kolkata, the vaccine had an 60 efficacy of 43% after 5 years compared to 65% in the 5-15 years of age group (8, 9) . The only 61 OCV to be approved by the FDA in the United States, Vaxchora, comprises a live-attenuated O1 62
Classical Inaba strain, with 94% of the ctxA gene encoding the enzymatic subunit of CT deleted 63 and replaced by a mercury-resistance cassette, while leaving the ctxB gene intact. While the 64 5 vaccine was safe and immunogenic in US trials (10), it had a less than desirable outcome of 14% 65 protection in a large Bangladesh field trial (6). 66
We hypothesized that one contributor to this high level of geographical variation in OCV 67 efficacy may be variations in the microbial populations of the gut, the gut microbiome. Several 68 studies have shown that gut bacterial populations can change due to diet and geography (11, 69 12) , especially when comparing populations in the United States and Europe versus those in 70 developing countries (13) (14) (15) . While the presence of a normal murine microbiome has been 71 implicated in antibody responses against viral vaccines (16), the effects of a human gut 72 microbiome on responses to V. cholerae or other enteropathogenic bacteria have not been 73 well determined. To begin to address this question, we have assembled human fecal bacterial 74 communities that are representative of either bacteria that are commonly found in healthy 75 human guts (17) or bacteria prevalent in malnutrition or diarrhea endemic regions based on 76 existing 16S ribosomal DNA amplicon surveys (11, 18) . Here, we show that dysbiotic gut 77 bacterial populations at time of V. cholerae immunization dampen antigen-specific antibody 78 responses against V. cholerae in a CD4+-cell-dependent manner. These findings suggest that gut 79 bacterial composition at time of immunization may impact adaptive immune responses to V. 80 cholerae and may be applicable to other enteric pathogens as well. 81 82 6
Results

83
To begin to examine the role of human microbiome structure on vaccination outcomes, we 84 established model human fecal communities in adult CD-1 mice. Preclinical studies in animal 85 models are essential to understand the intricate mechanisms of vaccine protection. There are 86 several animal models for studying V. cholerae, the most widely used being the infant mouse 87 cholera model (19) . However, while the suckling animals can be used to study Vibrio 88 colonization and virulence, they are poorly suited for immunological studies, as the infant 89 mouse does not have a fully developed adaptive immune system, a limitation shared by the 90 recently developed infant rabbit model of cholera (20, 21) . Others have utilized germ-free adult 91 mice to evaluate immune responses to V. cholerae (22), but there may be limitations to this 92 approach as well because there are no microbial-immune system interactions at birth, which 93 are critical to a robust development of adaptive immunity (23). However, depletion of the 94 murine microflora is critical to examining the effects of human microbial communities, as 95 mouse-adapted microbes rapidly out-compete non-murine communities (24). Thus, we used 96 antibiotics to treat adult animals (25) in order to allow the introduction of human gut 97 communities in an immune-competent animal system. Adult CD-1 mice were treated with an 98 antibiotic cocktail for 1 week (See Materials and Methods) and then switched to streptomycin 99 treatment alone 3 days before the gavage (Fig. 1A) . The mice were then gavaged with ~5 x 10 9 100 CFU of V. cholerae C6706 O1 El Tor. We observed that antibiotic treatment was critical to 101 eliciting antibody responses against immunization ( Fig. 1B) . Serum vibriospecific ELISA showed 102 that levels of IgG3 and IgM, strong complement fixing antibodies, were decreased in the NM 103 group as compared to the DM group ( Fig 1C) .
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We then moved to establish human gut communities in these antibiotic cleared mice. As 105 a proof of principle, we constructed simplified defined communities of human gut isolates, 106 designed on the basis of metagenomic surveys of individuals in cholera-endemic areas, but 107 nonetheless simple enough to be easily and reproducibly deployed in numerous animal 108 experiments. We constructed two embodiments, the NM microbiome, broadly representative 109 of healthy microbiomes (13, 26) and the DM model microbiome, which closely resembled 110 dysbiotic human gut microbial communities in areas affected by malnutrition and diarrhea, 111 including cholera (11, 17, 18, 27) (Table S1 ). 112
At 2 weeks post introduction of V. cholerae the mice were switched to ampicillin, 113 neomycin, and vancomycin in drinking water. We re-introduced strong antibiotic control of 114 microbial growth in these animals for two reasons. First, we wanted to remove V. cholerae so 115 that potentially varying levels of antigen present over time would not affect immune responses; 116 germ-free adult mice show sustained colonization, while human gut microbial communities 117 have been shown to affect colonization levels in mice (17). Shedding of V. cholerae in Vaxchora 118 recipients has been minimal, and continued bacterial carriage for any vaccine is 119 disadvantageous for safety reasons (28). In addition, we wanted to remove the introduced 120 human microbiomes after they had had the opportunity to influence responses to V. cholerae, 121 and before any potential long-term fluctuations in the community can induce 122 immunomodulatory effects on the host. We reasoned that this approach also more closely 123 approaches practice in vaccine deployment in humans in endemic areas. Individuals suffering 124 from malnutrition and various forms of infectious diarrheas in Bangladesh have demonstrated a 125 strong but transient shift in fecal microbial composition to the DM community structure (18). 126 8 This temporary dysbiosis is likely to affect a substantial portion of human vaccine recipients, 127 and has not served as an exclusion criteria for prior vaccine trials. 128
At 4 weeks post introduction of V. cholerae, serum and fecal samples were collected 129 from immunized mice containing NM and DM human microbiomes. To evaluate the efficacy of 130 anti-V. cholerae antibody responses, we used a serum vibriocidal assay, which is considered to 131 be the best clinical correlate of protection for cholera (29) (30) (31) (32) . The vibriocidal titer is the 132 reciprocal of the highest dilution of serum at which killing of V. cholerae is observed with the 133 addition of exogenous complement. Briefly, serum from immunized animals is heat-inactivated 134 and diluted in two-fold steps, after which a mixture of guinea pig complement and V. cholerae 135 are added to each serum sample. After incubation, V. cholerae growth is observed by plating on 136 selective solid medium. In humans, a clinically successful seroconversion as a result of 137 vaccination is defined as a more than four-fold rise in serum vibriocidal titers compared to 138 baseline pre-immune titer over two weeks , although there is no defined titer at which 139 protection can be considered to be definitively achieved (33). We observed that serum from 140 animals bearing the (DM) microbiome at time of infection exhibited a statistically significant 141 reduction in serum vibriocidal activity compared to that from animals immunized in the 142 presence of the (NM) microbiome (Fig 2) , suggesting that the presence of members of the 143 dysbiotic community at time of immunization may hinder the development of a robust serum 144 antibody response. 145
Although the vibriocidal assay represents a good correlate of protection in humans, we 146 used a passive protection assay to determine a more functional measure of the activity of 147 antibody generated by immunized animals. While serum vibriocidal activity is mostly due to the 148 9 action of IgG and IgM, protection from infection is thought to be primarily mediated by 149 secreted antibodies, especially secretory antibodies at the site of infection, i.e. the intestinal 150 mucosa. During the course of infection, class-switching to IgA and the secretion of antigen-151 specific secretory IgA (s-IgA) serves as the main means of protection by binding to V. cholerae 152 and preventing pathogen access to epithelium, and neutralizing cholera toxin (34). A recent 153 study highlights the capacity of a monoclonal IgA antibody to inhibit V. cholerae motility, 154 preventing access to the intestinal epithelium (35). IgA is not likely to be well reflected in 155 serum; the bulk of IgA in the body is secretory IgA (s-IgA) secreted in gram quantities onto the 156 mucosa (36). To obtain this secreted antibody from vaccinated animals, fecal immunoglobulin 157 from both NM and DM animals was purified using a Protein L Purification Kit (Pierce). These 158 antibody pools were predominantly IgA with low levels of IgM ( Fig 3A) . Purified Ig from both 159 groups was combined with V. cholerae grown overnight and incubated for 1 hour before being 160 gavaged into 4-day old infant CD-1 mice. Suckling animals were used as conventionally-reared 161 adult animals are highly resistant to V. cholerae colonization (37, 38). After 18 hours of 162 infection, the small intestines were homogenized and plated on selective medium. We 163 observed that pre-treatment with antibody from animals bearing the dysbiotic microbiome led 164 to colonization nearly 2-log greater than pre-infection treatment with antibody from animals 165 with the NM microbiome ( Fig. 3B ). Taken together, these findings suggested that oral 166 immunization in a DM microbiome context lead to a significantly less effective anti-Vibrio 167 antibody response. 168
To determine whether the NM or DM phenotype would be dominant when the bacterial 169 communities are combined, we immunized mice with V. cholerae in the presence of either NM, 170 10 DM, or NM+DM microbiomes. At 4 weeks post immunization, the NM+DM group showed a low 171 serum vibriocidal titer comparable with the DM group, while the NM group had significantly 172 higher titer levels (Fig. 4A) . These data suggested that the dysbiotic microbiome may have a 173 role in suppressing the antibody response against V. cholerae. 174
Due to the reduced vibriocidal titer levels observed in the NM+DM group, we wanted to 175 determine whether or not live members of the susceptible community were required to 176 mediate this effect. Accordingly, we heat inactivated all the members of the respective 177 communities and again immunized mice with live V. cholerae. When we heat inactivated our 178 bacterial communities, we observed that the serum vibriocidal titer increased in the DM group 179 to similar levels with the NM group (Fig. 4B) . These findings suggest that live members of the 180 dysbiotic community are necessary at time of immunization in order to mediate suppression of 181 anti-Vibrio antibody protection. 182
In general, the mechanistic immune responses to OCVs remains to be fully determined. 183
The initial response appears to be driven by TLR-2 interactions that can cause CD4 + 184 proliferation, and it has been shown that CD4 + T cells are also instrumental in stimulating long-185 term memory B cell responses (39-42). We therefore further examined the role of CD4 + T cells 186 in the context of our DM-mediated suppression of anti-V. cholerae antibody responses by 187 depleting CD4 + cells in mice co-inoculated with V. cholerae and model human microbiomes. 188
Adult CD-1 mice were intraperitoneally injected with anti-CD4 monoclonal antibodies every 4 189 days during antibiotic treatment. After verifying depletion of CD4 + cells by flow cytometry 190 analysis of serum ( Fig. 5A-B) , animals were gavaged with live defined microbial communities 191 and V. cholerae as previously mentioned. Levels of serum anti-V. cholerae IgA were severely 192 11 reduced in both groups (Fig 5C) , while there were no significant differences in levels of serum 193
IgG and IgM. Strikingly, vibriocidal titer in the DM group increased to levels comparable to the 194 NM group after CD4 + cell depletion (Fig. 5D ). This level was also comparable to that observed in 195 NM group without depletion, suggesting that CD4 + cells are not required for the development 196 Efficacy of vaccination against enteric pathogens has been shown to be highly variable on a 203 geographical and per-study basis, including for rotavirus (43), Salmonella (44), polio(45), and 204 cholera (2). One of the potential reasons for the variability may be due to interpersonal 205 variations in gut microbiomes (46) . Previous studies sought to identify the relative abundance 206 of certain species that were either positively or negatively correlated with protection, but were 207 unable to translate these findings into an experimental model of vaccine efficacy. Using 208 microbiome replacement in antibiotic-treated mice, our experiments suggest that the 209 composition of the human gut microbiome at time of immunization suppresses the antibody-210 mediated immune response against V. cholerae. We observed that the presence of the 211 dysbiotic community at time of immunization was sufficient to dampen antibody-mediated 212 protection. Since this required live, as opposed to heat-killed, DM community organisms, these 213 data suggest that certain microbiome structures are actively suppressive of responses to 214 vaccination. There are relatively few studies that have looked at how a community in dysbiosis 215 may alter the humoral immune response. One study shows that Sutterella species are capable 216 of degrading the stabilizing peptide of sIgA, leading to decreased levels of IgA (47). The 217 mechanism in our studies is likely different, as our microbial populations are only transiently 218 present, and overall antibody levels are comparable across different model microbiomes. 219 While in humans, the gut microbiome enters a DM-like state transiently after infectious 220 diarrhea, repeated infection by multiple pathogens, from cholera to pathogenic Escherichia coli 221 and rotavirus, means that this state is much more frequently attained in cholera-endemic areas 222 (11, 17, 18) . Malnutrition, another common public health concern often co-occurring with 223 13 recurrent infectious diarrhea, induces a DM-like state for much longer periods, and is refractory 224 to therapeutic nutritional intervention (48). Our DM model community is also similar to the 225 DM-like community state in humans due to its dramatically lower diversity; human 226 microbiomes during fulminant diarrhea and early recovery from diarrhea can be dominated by 227 99% Streptococcus species by relative abundance (17). The definition for what constitutes a 228 truly "healthy" microbiome is not settled. While our NM model community is very broadly 229 reflective of healthy human communities by higher taxonomy levels, interpersonal and 230 temporal intrapersonal variation in healthy individuals can potentially lead to other effects on 231 vaccination outcome not fully captured by our NM-replacement model. More studies with 232 complex human fecal communities will be necessary to probe temporal variations in 233 interactions between the host and the broad range of microbiome structures seen in healthy 234
humans. 235
Our antibiotic treated adult mouse experimental system is a robust model to study gut 236 microbiota interactions in the host. In contrast to previous studies (22), we are able to 237 transplant actual human microbes into an immune-competent animal system, shortening the 238 loop from initial observations to potentially clinically-relevant conclusions. In contrast, 239 germfree mice have limitations for immune studies; 'dirty' mice such as feral and pet store mice 240 display a more mature immune response due to more complete microbial exposure and 241 consequent immune development (49, 50) . 242
To begin teasing apart the host mechanism behind this microbiome-dependent antibody 243 response phenotype, we examined the role of CD4 + T cells. Upon depletion of CD4 + cells, we 244 observed decreased levels of serum IgA after immunization in both NM and DM mice, 245 14 potentially indicating decreased seroconversion (Fig. 5C ). However, serum vibriocidal titer in 246 DM, CD4 + -depleted animals increased to levels comparable to the NM mice (Fig. 5D ). These 247 data show that CD4 + cells are integral in mediating microbiome-dependent changes in an 248 immunization-induced antibody response. These results are surprising as one would expect 249 CD4 + T cell depletion to substantially reduce the vibriocidal titer but our data suggests that 250 there are compensatory, non-CD4 + mediated mechanisms to aid in seroconversion. A recent 251 clinical study evaluating the efficacy of the oral cholera vaccine Shanchol in human 252 immunodeficiency virus (HIV)-infected individuals demonstrated that while vibriocidal titer was 253 lower in HIV-infected individuals with depleted CD4 + T-cell populations there was still 254 seroconversion in 65-74% of the subjects (51). While the study population was not completely 255 depleted of CD4 + T cells, it demonstrates vibriocidal titers can be elicited even in a highly-CD4 + 256 cell-depleted state, albeit to a lesser degree. 257
In order to more fully understand the correlations between bacterial communities, V. 258 cholerae, and host interactions, more work will need to be done to study the biochemical 259 underpinnings of microbiome-host interaction as it impacts vaccination. The interface between 260 DM microbes and the immune system is yet to be defined; the inability of heat-killed DM 261 communities to influence vaccine outcomes suggest that an active interaction with host tissue, 262 or the production of active compounds in vivo are required for this. At the host level, while we 263 investigated the role of CD4 + T cells in this phenotype, other immune cell types such as antigen 264 presenting cells may act as more direct intermediaries between host immunity and microbial Female CD-1 mice were purchased from Charles River Laboratories, and generally used at 5-9 286 weeks of age. 4-day old suckling CD-1 mice were purchased from Charles River Laboratories. 287
Animals in the study were treated and housed under specific-pathogen-free conditions. All 288 animal protocols were approved by University of California, Riverside's Institutional Animal 289
Care and Use Committee. 290 291
Bacterial strains and growth conditions: 292
All human gut commensal strains used are listed in Table S1 . Unless otherwise noted, human 293 gut strains were propagated in LYHBHI liquid medium (BHI supplemented to 5g/L yeast extract, 294 5mg/L hemin, 1mg/mL cellobiose, 1mg/mL maltose and 0.5mg/mL cysteine-HCl). Cultures were 295 then grown in a Coy anaerobic chamber (atmosphere 5% H 2 , 20% CO 2 , balance N 2 ) or 296 aerobically at 37 o C. All V. cholerae strains were derived from the C6706 El Tor pandemic isolate 297 and propagated in LB media with appropriate antibiotics at 37°C. 298 299
Preparation of bacteria for inoculation into antibiotic treated mice 300
Female adult CD-1 mice were given an antibiotic cocktail ad libidum (1 g/L ampicillin, 1 g/L 301 neomycin, and 125 mg/L vancomycin)(52, 53), and for 1 week as described previously with 302 modifications as mice refrained from drinking water with metronidazole (54). 2.5 g/L of Splenda 303 was added as well to make the cocktail more palatable. 3 days prior to gavage with V. cholerae, 304 17 the cocktail was replaced with 2.5 g/L streptomycin and 2.5 g/L Splenda. Each anaerobic human 305 gut bacterium was cultured from glycerol stocks in LYHBHI media for 24 hours at 37°C, and then 306 diluted (1:50) in fresh LYHBHI media. Enterococcus faecalis and Escherichia coli were grown 307 aerobically in LYHBHI and LB, respectively, for 24 hours at 37°C, and then diluted (1:50) in 308 respective media. After growth for an additional 48 hours, cultures were normalized for density 309 by OD 600 . For inoculation into adult mice, normalized mixtures were prepared so the equivalent 310 total of 300 L of OD 600 =0.4 culture divided evenly across the respective strains for each 311 community was pooled, centrifuged, and resuspended in LYHBHI. The suspension was prepared 312 so that each mouse received 50 L of the bacterial community mixture, as well as 50 L 313
containing ~5 x 10 9 V. cholerae O1 El Tor C6706. Prior to bacterial introduction, the mice were 314 fasted for 3 hours and then gavaged with 100 L of 1 M NaHCO 3 , to buffer stomach acid, after 315 which the bacterial communities and V. cholerae were inoculated via oral gavage. 316 317
Serum vibriocidal assay: 318
Mouse whole blood was collected via tail vein bleeds using heparinized Caraway collection 319 tubes (Fisher Scientific). Blood was centrifuged at 9,000 x g for 10 minutes, and the serum 320 fraction was isolated and stored at -20°C. The vibriocidal titer measurement was done as 321 previously described with minor modifications (55). In brief, mouse serum was heat inactivated 322 for 30 minutes at 56°C. The heat-inactivated serum was then serially diluted two-fold with 323 phosphate-buffered saline (PBS). Separately, PBS, guinea pig complement serum Aldrich), and ~ 5 x 10 8 CFU V. cholerae were combined at a ratio of 7:2:1, respectively. The 325 above mixture was then added to the wells containing serially diluted serum and incubated at 326 37°C for two hours. The resulting dilutions were then plated onto streptomycin ( 
Passive immune protection assay: 357
Fecal samples from immunized animals bearing the NM and DM communities was collected and 358 processed as described previously. Total IgA/IgM fecal antibody was purified using Protein L 359 magnetic beads according to the manufacturer's protocol (Pierce Biotech). 50 ng of pure 360 antibody was bound to ~1.25 x 10 6 CFU V. cholerae and allowed to bind at 37°C for 1 hour. 4-361 day old suckling CD-1 mice were gavaged with 30-gauge plastic tubing with 50 μL of antibody/V. 362 cholerae mixture. After 18 hours of infection, the animals were sacrificed, and intestines 363 homogenized for V. cholerae CFU enumeration on selective medium. 364 365
Preparation of heat-killed commensal bacteria 366
Strains from the NM and DM communities were grown in pure cultures and the bacterial 367 suspension was prepared as previously mentioned. The respective bacterial communities were 368 killed by heating in a heat block for 1 hour at 100°C. Bacterial death was confirmed by plating 369 onto solid media and observing lack of growth. 370 20 371
In vivo depletion of CD4 + cells 372
In order to deplete CD4 + cells in vivo, 50 L of GK1.5 antibody (Bio X Cell) was administered 373 intraperitoneally every four days at a concentration of 100 μg/mL. Depletion of CD4 + cells in 374 blood was confirmed using a FACS Canto flow cytometer (BD Biosciences) and FITC rat-anti-375 mouse CD4 (BD Biosciences). Red blood cell lysis was done using ACK lysis buffer and CD16/32 376 was used as an Fc block. Analysis was done using Flow Jo (BD Biosciences) and Prism 377 (GraphPad). Mice were treated with ampicillin, neomycin, and vancomycin as previously 378 mentioned. 3 days prior to infection, the mice were placed on streptomycin water alone. The 379 mice were infected with ~5 x 10 9 CFU V. cholerae and serum vibriospecific ELISAs and 380 vibriocidal assays were performed as previously described. 381 382 Acknowledgments 383
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